Loading clinical trials...

Tiotropium / Respimat One-Year Study | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Tiotropium / Respimat One-Year Study

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00168831•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Criteria
•Patients with stable moderate to severe COPD and a smoking history of at least 10 pack years were eligible for inclusion in the study. Patients with significant diseases other than COPD were excluded as were patients with a recent history of myocardial infarction, history of malignancy, unstable or life-threatening cardiac arrhythmia, narrow-angle glaucoma, asthma or other allergic conditions. Patients treated with cromolyn, nedocromil, oral beta-adrenergics or unstable doses of oral corticosteroids were ineligible for inclusion in the study as were patients who had received previous treatment with tiotropium.

Locations (76)

Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Boehringer Ingelheim Investigational Site

La Jolla, California, United States

Boehringer Ingelheim Investigational Site

Long Beach, California, United States

Boehringer Ingelheim Investigational Site

San Luis Obispo, California, United States

Boehringer Ingelheim Investigational Site

Gainesville, Florida, United States

Boehringer Ingelheim Investigational Site

Hallandale, Florida, United States

Boehringer Ingelheim Investigational Site

Hines, Illinois, United States

Boehringer Ingelheim Investigational Site

Chesterfield, Missouri, United States

Boehringer Ingelheim Investigational Site

Bay Shore, New York, United States

Boehringer Ingelheim Investigational Site

Charleston, South Carolina, United States

Key Dates

Start Date

February 1, 2003

Primary Completion Date

June 1, 2005

Last Updated

May 20, 2014

Enrollment

1,007

ACTUAL participants

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Tiotropium Inhalation Solution

DRUG

Placebo

OTHER

Sponsors

Lead Sponsor

Boehringer Ingelheim

Related Studies

Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity

NCT06831994

Asthma BronchialeBreast Neoplasms+11 more

The London COPD Exacerbation Cohort

NCT02755974

Pulmonary Disease, Chronic Obstructive

ACTIVE_NOT_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 20, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions